JOURNAL ARTICLE
MR imaging of Hippel-Lindau disease: value of gadopentetate dimeglumine.
Hippel-Lindau disease is an autosomal dominant disorder characterized by tumors of the central nervous system and abdominal viscera. Frequent multisystem radiologic evaluation of persons at risk is desirable. Twenty-seven patients with Hippel-Lindau disease or a family history of the disease were examined with both unenhanced and gadopentetate dimeglumine-enhanced magnetic resonance (MR) imaging to study the usefulness of the contrast medium in the evaluation of these patients. The MR studies were correlated with computed tomographic (CT) scans in seven patients and cerebral angiograms in five. Twelve patients had hemangioblastomas in the brain, and eight of these patients also had spinal cord lesions (most were multiple), well demonstrated with gadopentetate dimeglumine. Contrast-enhanced MR imaging enabled detection of more central nervous system lesions and provided better delineation than unenhanced MR imaging, CT, or angiography. In addition, four patients with multiple renal cysts seen on CT scans and unenhanced MR images had enhancing lesions that were later proved to be renal cell carcinoma at angiography and/or surgery. Four patients had cystic lesions in the pancreas that did not enhance and were later proved to be pancreatic cysts. The authors conclude that gadopentetate dimeglumine-enhanced MR imaging appears to be a useful method for evaluating and following up patients with Hippel-Lindau disease.
Full text links
Trending Papers
Management of Hemorrhagic Shock: Physiology Approach, Timing and Strategies.Journal of Clinical Medicine 2022 December 30
New antibiotics for Gram-negative pneumonia.European Respiratory Review : An Official Journal of the European Respiratory Society 2022 December 32
Migraine.Annals of Internal Medicine 2023 January 11
How to diagnose iron deficiency in chronic disease: A review of current methods and potential marker for the outcome.European Journal of Medical Research 2023 January 10
New therapies for obesity.Cardiovascular Research 2022 November 31
Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology.Swiss Medical Weekly 2023 January 7
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app